Acrivon Therapeutics (NASDAQ:ACRV) unveiled promising interim data from its lead oncology program on Thursday, demonstrating that its biomarker-driven approach can achieve significant results in patients with hard-to-treat serous endometrial cancer.
The company’s lead candidate, ACR-368, a selective CHK1/2 inhibitor, showed a 67% confirmed objective response rate (cORR) in a subset of patients identified by Acrivon’s proprietary "OncoSignature" biomarker.
Across a broader group of serous endometrial cancer patients, the drug achieved a 52% cORR, a notable figure for a population that has typically failed multiple lines of prior therapy, including chemotherapy and immunotherapy.
"These results are consistent with serous tumors being G1-S-deficient, leading to a dependency on the G2-M checkpoint controlled by CHK1/2," the company said.
To accelerate the drug's path to market, Acrivon has submitted a Phase 3 protocol for a combination study with anti-PD-1 therapy and plans to open more than 20 clinical sites across Germany, Italy, France, and Spain in early 2026.
Beyond its lead asset, Acrivon reported initial Phase 1 success for ACR-2316, a dual WEE1/PKMYT1 inhibitor.
In a study of 33 patients, the drug induced tumor shrinkage in nearly half of the evaluable subjects at higher dose levels, including a confirmed partial response in endometrial cancer.
The company is also moving its third candidate, ACR-6840, toward an IND submission in late 2026.
Financially, the Watertown, Massachusetts-based biotech remains on stable footing.
Acrivon ended 2025 with approximately $119 million in cash and investments, which it expects will fund operations into the second quarter of 2027.
This runway covers several critical catalysts, including the completion of enrollment for its ACR-368 "biopsy-free" Arm 3 trial, which is slated for the fourth quarter of 2026.